Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Rifaximin plus lactulose effectively reduces overt hepatic encephalopathy (HE) recurrence and hospitalizations in cirrhosis patients. This combination therapy shows significant benefits across various patient subgroups.
Area Of Science
- Hepatology
- Pharmacology
- Clinical Trials
Background
- Cirrhosis patients are at high risk for overt hepatic encephalopathy (HE).
- Comorbidities like ascites and diabetes can influence HE development and treatment efficacy.
- Stratification by baseline characteristics is crucial for understanding treatment outcomes.
Purpose Of The Study
- To evaluate the efficacy of rifaximin plus lactulose compared to lactulose alone.
- To assess treatment effectiveness in cirrhosis patients at risk for overt HE.
- To analyze outcomes based on baseline characteristics such as ascites and diabetes.
Main Methods
- Pooled post hoc subgroup analysis from a phase 3 randomized, double-blind trial and a phase 4 open-label trial.
- Adult patients received rifaximin 550 mg twice daily plus lactulose or lactulose alone for 6 months.
- Analysis stratified patients by key baseline characteristics.
Main Results
- Rifaximin plus lactulose demonstrated greater efficacy than lactulose alone.
- The combination therapy significantly reduced the risk of overt HE recurrence.
- HE-related hospitalizations were also reduced in the rifaximin plus lactulose group.
Conclusions
- Rifaximin plus lactulose is more efficacious in preventing overt HE recurrence and HE-related hospitalizations.
- The benefits of combination therapy are observed across specific baseline disease characteristics.
- This supports the use of rifaximin plus lactulose for managing HE risk in select cirrhosis patients.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
Lifestyle adjustments often incorporate stress reduction techniques like yoga, meditation, and regular physical activity to alleviate symptoms like bloating and constipation.
A critical component of dietary management is the introduction of soluble fiber, which can be found in foods like oats, barley, apples, and carrots. Restricting and then gradually...